Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immunotherapy of multiple myeloma

Educational leadership(2020)10.1172/jci129205Source: DataRank Database

Immunotherapy of multiple myeloma is a research paper published in Educational leadership (2020). On theSindex it has a DataRank of 0. It has been cited 219 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access219 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: bronzeTopics (24)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Geoffrey R. Hill ORCID,Simone A. Minnie ORCID

Live enrichment

PubMed:32149732

National Institutes of Health

Grant: 3U01CA244291-02S1

Optimizing myeloma-specific immunity after autologous stem cell transplantation

NCI NIH HHS

Grant: U01 CA244291

bronze

publisherhttp://www.jci.org/articles/view/129205/files/pdf

publisherhttps://www.jci.org/articles/view/129205/files/pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7108923

https://doi.org/10.1172/jci129205

https://pubmed.ncbi.nlm.nih.gov/32149732

Fields of Study

0301 basic medicine03 medical and health sciences0302 clinical medicineHematopoietic Stem Cell TransplantationHumansImmunotherapyMultiple MyelomaTransplantation, AutologousTumor Microenvironment

MeSH Terms

Hematopoietic Stem Cell TransplantationHumansImmunotherapyMultiple MyelomaTransplantation, AutologousTumor Microenvironment

Keywords

2700 MedicineHematopoietic Stem Cell TransplantationTumor Microenvironment610HumansGeneral MedicineImmunotherapyMultiple MyelomaTransplantation, Autologous

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 2 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616683.v1figshare

Additional file 2 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616683figshare

Additional file 3 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616686.v1figshare

Additional file 3 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616686figshare

Additional file 4 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616689.v1figshare

Additional file 4 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616689figshare

Additional file 5 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616692.v1figshare

Additional file 5 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616692figshare

Additional file 6 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616695.v1figshare

Additional file 6 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616695figshare

Additional file 7 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616698.v1figshare

Additional file 7 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

10.6084/m9.figshare.22616698figshare

Additional file 1 of The implication of serum HLA-G in angiogenesis of multiple myeloma

10.6084/m9.figshare.26043769.v1figshare

Additional file 1 of The implication of serum HLA-G in angiogenesis of multiple myeloma

10.6084/m9.figshare.26043769figshare

Additional file 1 of PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients

10.6084/m9.figshare.26555609.v1figshare

Additional file 1 of PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients

10.6084/m9.figshare.26555609figshare

Additional file 1 of Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myeloma

10.6084/m9.figshare.26698886.v1figshare

Additional file 1 of Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myeloma

10.6084/m9.figshare.26698886figshare

Additional file 4 of Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myeloma

10.6084/m9.figshare.26698895figshare

Additional file 3 of Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myeloma

10.6084/m9.figshare.26698892.v1figshare